Lilly Raises Full-Year Earnings Forecasts On Surging Demand For Weight-Loss Drug

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk’s Wegovy.